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Original paper

Clinical Investigations

Dosimetric differences between cesium-131
and iodine-125 brachytherapy for the treatment
of resected brain metastases
Menachem Z. Yondorf, BA1,2, Shahdabul Faraz, BS1, Andrew W. Smith, BA3, Albert Sabbas, PhD1, Bhupesh Parashar, MD1,
Theodore H. Schwartz, MD4, A. Gabriella Wernicke, MD, MSc1,4
1Department

of Radiation Oncology, Weill Medical College of Cornell University, New York, USA, 2Department of Radiation Oncology,
Thomas Jefferson University Hospital, Philadelphia, USA, 3University of Rochester School of Medicine and Dentistry, Rochester, New York, USA,
4Department of Neurosurgery, Weill Medical College of Cornell University, New York, NY, USA

Abstract
Purpose: To compare treatment plans and evaluate dosimetric characteristics of permanent cesium-131 (131Cs) vs.
iodine-125 (125I) implants used in brain brachytherapy.
Material and methods: Twenty-four patients with 131Cs implants from a prospective phase I/II trial were re-planned
with 125I implants. In order to evaluate the volume of brain tissue exposed to radiation therapy (RT), the dose volume
histogram was generated for both radioisotopes. To evaluate the dosimetric differences of the two radioisotopes we
compared homogeneity (HI) and conformity indices (CI), and dose covering 100% (D100), 90% (D90), 80% (D80), and
50% (D50) of the clinical target volume (CTV).
Results: At the 100%, 90%, 80%, and 50% isodose lines, the 131Cs plans exposed less mean volume of brain tissue
than the 125I plans (p < 0.001). The D100, D90, D80, and D50 were smaller for 131Cs (p < 0.001). The HI and CI for 131Cs vs.
125I were 19.71 vs. 29.04 and 1.31 vs. 1.92, respectively (p < 0.001).
Conclusions: Compared to 125I, 131Cs exposed smaller volumes of brain tissue to equivalent doses of radiation and
delivered lower radiation doses to equivalent volumes of the CTV. 131Cs exhibited a higher HI, indicating increased
uniformity of doses within the CTV. Lastly, 131Cs presented a CI closer to 1, indicating that the total volume receiving
the prescription dose was closer to the desired CTV volume. These results suggest that 131Cs is dosimetrically superior
to 125I and may explain the reason for the 0% incidence of radiation necrosis (RN) in our previously published prospective study using 131Cs.
J Contemp Brachytherapy 2020; 12, 4: 311–316
DOI: https://doi.org/10.5114/jcb.2020.98109
Key words: cesium-131 (131Cs), iodine-125 (125I), brachytherapy, metastases, recurrence, radiation necrosis.

Purpose
Over the last decade, the rise in the length of survival for cancer patients has led to an increased incidence
of brain metastases. Brain metastases have now been
shown to occur in up to 40% of cancer patients and are
the most common cause of intracranial tumors [1]. Without treatment, the prognosis is grim, with survival of only
1-2 months [2]. Surgical resection of the metastases has
been shown to increase overall survival [3]. Resection,
however, often requires adjuvant irradiation in the form
of stereotactic radiosurgery (SRS) or whole-brain radiotherapy (WBRT) in order to prevent local recurrence. Due
to WBRT’s quality of life concerns, its late toxicity profile and the fact that it offers no overall survival benefit
compared to more local therapy, recent focus has shift-

ed towards the potential of local post-resection options,
such as SRS and intra-operative brachytherapy [4,5,6,7].
Brachytherapy, in particular, has received considerable
interest as it offers some advantages even over SRS,
namely its absence of a long-time frame that can allow
tumor cell repopulation [4,8]. A recent study that our
group has published has shown that surgical resection
and intra-operative brachytherapy is more cost-effective
compared to surgical resection and SRS in the treatment
of brain metastasis [9]. Additionally, it is known that SRS
does not achieve optimal local control for large (greater
> 3 cm) and irregularly-shaped cavities [9].
Intra-operative brachytherapy implants have been
utilized for the prevention of local recurrence in cases of
brain metastases. Brachytherapy has historically utilized
the iodine-125 (125I) radioisotope for both permanent and
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temporary seed implants [10]. The commonly used radioisotope 125I has a T1/2 of 59.4 days and has an average energy of 28.4 keV. These physical properties make 125I convenient for storage, with limited shielding. The clinical
results have revealed that although 125I has been shown
to confer local control comparable to that of post-operative SRS, the high rates of radiation necrosis (RN) associated with 125I brachytherapy have been criticized [11].
Cesium-131 (131Cs) is a relatively novel radioisotope, the Food and Drug Administration cleared in 2003,
which presents both physical and radio-biological advantages when compared to 125I brachytherapy. 131Cs has
a shorter T1/2 of 9.69 days compared to 59.4 days for 125I.
131Cs is more likely to be biologically efficient for the destruction of tumor cells, as the initial dose rate from 131Cs
(23.9 cGy/h) is 4 times higher than that of 125I (5.8 cGy/h)
[9,10]. Our institution was the first to report the results of
a prospective phase I/II trial demonstrating the effective
use of intra-operative application of 131Cs brachytherapy
for patients with newly diagnosed brain metastases [4].
In that study, we reported a 0% incidence of clinical RN.
This contrasts with the results reported by many studies
that used permanent 125I seeds, which has been associated
with an average RN rate of 14.4% (range, 0-26%) [12]. In
the present study, we investigated the dosimetric profile
of 131Cs brachytherapy compared to that of 125I in order to
understand this disparity in RN rates.

Follow-up physical evaluation and MRIs were performed
every 2 months thereafter. For the simulated 125I isotope
implants, the prescribed dose was 80 Gy as well. The exact implant scheme for 131Cs was used for the simulated
125I cases. Finally, RN was detected on follow-up MRIs
and confirmed by a combination of clinical judgement
and further imagine including perfusion, spectroscopy,
and positron emission tomography (PET) scans.

Dosimetric comparison of 131Cs vs. 125I
Dosimetric comparison was carried out for all included 24 patients. Post-operative dosimetry plans were generated using BrachyVision (Varian Medical Systems, Palo
Alto, CA, USA) for 131Cs seed model 131Cs Rev 2, and the
same CT data set was re-planned with 125I seeds using
model No 6711 (TG43). The mean air kerma strength for
the 131Cs and 125I seeds was 2.4 U (3.768 mCi) and 0.6985
U (0.55 mCi), respectively. The dose volume histogram
(DVH) was generated and from it, the volume of brain
tissue (cc) exposed to radiation at the 100%, 90%, 80%,
and 50% isodose lines were compared for both radioisotopes. From the DVH, the D100, D90, D80, and D50 were
obtained as well. Lastly, the homogeneity and conformity indices were calculated for each individual patient.
The equations used for HI and CI were as follows:
HI = D100 – D150/D100,
where D100 – volume enclosed by prescribed dose rate
and D150 – volume enclosed by 1.5 times prescribed dose
rate.

Material and methods
Patient characteristics
There were 24 patients in total, 14 females and 10
males, with a median age of 65 years (range, 45-84 years).
The brain metastases were located in the frontal (10), parie
tal (7), cerebellar (4), occipital (2), and temporal (1) regions.
The histology from the metastases was lung (16), breast (2),
kidney (2), melanoma (2), colon (1), and cervix (1).

Implantation procedure

CI = TV/CTV,
where TV – total volume receiving prescription dose and
CTV equals clinical target volume.
The different mean values between 131Cs and 125I were
compared using the Wilcoxon rank-rum test.

Results

Between 2010 and 2015, following Institutional Review Board approval, 24 patients were enrolled on a prospective trial at the New York Presbyterian/Weill Cornell
Medical Center, and underwent neurosurgical resection
and intra-operative 131Cs brachytherapy for newly diagnosed brain metastases. The metastases were detected in
each patient using a magnetic resonance imaging (MRI)
or computerized tomography (CT) scan. As described
previously [4], directly after resection, 131Cs stranded
seeds (IsoRay, Inc., Richland, WA, USA) with an activity
of 3-5 mCi were implanted, with a planned dose of 80 Gy
to a 5 mm depth from the surface of the resection cavity. At the time of resection, the seeds were secured with
Surgicel® (Ethicon, Inc., a Johnson & Johnson Company,
Somerville, NJ, USA) to prevent seed migration and alteration of dosimetry. Lastly, Tisseel® (Baxter International,
Inc., Deerfield, IL, USA), a fibrin glue, was also placed
within the cavity to limit cavity shrinkage and further
prevent seed dislodgement. Post-operative CT scans (GE
LightSpeed averaging 36.85 mGy) were performed within 48 hours after surgery to determine dose distribution.

Dosimetric comparison of 131Cs vs. 125I
The median volume of resected tumor based on
pre-operative MRI was 10.31 cc (range, 1.77-87.11 cc), intra-operative measurements of the cavity revealed a median volume of 3.13 cc (range, 1.00-17.00 cc), and median
number of seeds employed was 12 (range, 4-35 seeds).
The clinical data from these patients resulted in 100% local control, with median overall survival of 9.9 months,
and 0% incidence of RN. Table 1 shows the mean volume
of brain tissue exposed to radiation for each of the four
isodose lines from both 131Cs and 125I. At the 100% isodose
line, the mean volume of brain tissue exposed was 15.44 cc
(range, 2.50-52.78 cc) and 9.84 cc (range, 1.22-32.87 cc)
for 125I and 131Cs, respectively (p < 0.001). At the 90%
isodose line, the mean volume exposed was 17.51 cc
(range, 2.90-59.05 cc) and 11.31 cc (range, 1.47-37.59 cc)
for 125I and 131Cs, respectively (p < 0.001). At the 80% isodose line, the mean volume exposed was 19.96 cc (range,
3.30-67.20 cc) and 13.61 cc (range, 1.73-43.4 cc) for 125I and
131Cs, respectively (p < 0.001). At the 50% isodose line,
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the mean volume exposed was 33.40 cc (range, 6.30109.70 cc) and 23.38 cc (range, 3.39-76.14 cc) for 125I and
131Cs, respectively (p < 0.001). Consistently, for each isodose line, the mean volume of brain tissue exposed to radiation was significantly higher (on average, 52.0% higher)
for 125I than for 131Cs. Figure 1 displays three isodose lines
for both 125I and 131Cs seeds and superimposes them, allowing the clear visualization of the contrasting volumes
of brain tissue exposed to radiation.
As Table 2 shows, the D100 was 64.96 Gy (range,
46.46-10.90 Gy) and 43.99 Gy (range, 26.19-74.09 Gy) for
125I and 131Cs, respectively (p < 0.001). The D
90 was
119.02 Gy (range, 73.44-174.36 Gy) and 78.64 Gy (range,
40.31-136.36 Gy) for 125I and 131Cs, respectively (p < 0.001).
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Table 1. Mean volume of brain tissue exposed to
radiation doses at different isodose lines by 131Cs
and 125I isotopes
Isodose line

9.84

15.44

< 0.001

90%

11.31

17.51

< 0.001

80%

13.61

19.96

< 0.001

50%

23.38

33.40

< 0.001

B
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Mean volume Mean volume
of brain
of brain
tissue (cc)
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E

125I

131Cs

125I

131Cs

Fig. 1. Axial images of a patient who underwent neurosurgical resection and intra-operative brachytherapy demonstrating volume of brain tissue exposed to radiation across multiple isodose lines for each radioisotope and superimposed comparison between 131Cs and 125I isodose lines: A) plan using 125I, B) plan using 131Cs, C) 120 Gy isodose line, D) 80 Gy isodose line, E) 40 Gy
isodose line
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Table 2. Absolute doses of radiation delivered to
certain percent volume of CTV by 131Cs and 125I
isotopes
Percent volume
of CTV

Dose of
radiation
(Gy) 131Cs

Dose of
radiation
(Gy) 125I

p-value

100% (D100)

43.99

64.96

< 0.001

90% (D90)

78.64

119.02

< 0.001

80% (D80)

93.09

141.78

< 0.001

50% (D50)

134.79

206.17

< 0.001

Table 3. Comparison of homogeneity and conformity indices for 131Cs and 125I
Index

131Cs

125I

p-value

Homogeneity index

0.315

0.113

< 0.001

1.31

1.92

< 0.001

Conformity index

The D80 was 141.78 Gy (range, 84.02-203.02 Gy) and
93.09 Gy (range, 45.80-161.16 Gy) for 125I and 131Cs, respectively (p < 0.001). The D50 was 206.17 Gy (range,
113.69-289.32 Gy) and 134.79 Gy (range, 61.85-228.86 Gy)
for 125I and 131Cs, respectively (p < 0.001). At each percent
volume of the CTV, the dose delivered by 125I was significantly higher (on average, 51.0% higher) than for 131Cs.
The HI with respect to 131Cs and 125I were 0.312
(range, 0.15-0.50) and 0.113 (range, 0-0.34), respectively
(p < 0.001). The CI for 131Cs and 125I were 1.31 (range,
0.71-4.12) and 1.92 (range, 0.90-3.92), respectively (p < 0.001).
These results are summarized in Table 3.

Discussion
The use of permanent brachytherapy seed implants
for the treatment of brain metastases is advantageous,
since it can provide a treatment to a highly localized area.
This benefit allows the physician to precisely target a defined treatment volume and to avoid the surrounding tissues from potential damage. Permanent brachytherapy
offers several more advantages compared to WBRT and
SRS. The use of post-operative SRS may require a timeframe of 2-6 weeks after surgical resection in order to
facilitate wound healing and stabilization of the cavity
[4]. This delay in treatment may facilitate tumor cell repopulation. Similarly, concerns regarding the non-localized nature of WBRT and its toxicity profile have likely
contributed to the modest decrease in WBRT use. For
instance, WBRT’s acute toxicity profile includes fatigue,
edema, nausea, vomiting, and decreased appetite [13].
While these acute effects are typically resolved spontaneously or can be effectively treated, the late toxic effects
of WBRT are potentially more dangerous. This includes
potentially irreversible neurocognitive damage, leukoencephalopathy, and radiation necrosis [12]. Permanent
brachytherapy also offers a quality of life benefit that
must be considered. Both the tumor resection and subsequent seed implantation occurs during one procedure,

which is likely to increase patient satisfaction and convenience. These reasons, along with its cost benefits, provide justification for the increased interest in permanent
brachytherapy. Given this context, we believe our results
have a widespread applicability and may inform future
clinical decisions.
There have been several studies reported in the literature employing the use of brachytherapy seeds for the
treatment of brain metastases in the post-resection setting. Several studies have focused on the use of temporary 125I seeds, which allow for high-dose-rate delivery;
however, many of these studies were performed after biopsy alone, and patients did not receive maximal possible
resection. The more recent studies have used permanent
brachytherapy seeds, of which the majority of them employed 125I. Unfortunately, most of these studies are retrospective in nature, and therefore encompass a diverse
patient cohort and may be influenced by selection bias.
Furthermore, these studies often include patients with
both newly diagnosed brain metastases and those with
recurrences. Taking these factors into account, the reported median survival for the treatment of newly diagnosed
brain metastases ranges from 9.3-17.8 months and is associated with local control rates of 60-100%, with radiation
necrosis rates of 0-26% [11]. These data compare favorably to surgical resection plus SRS in terms of both the
median survival of 14 months as well as the local control
rates of 85% [14].
The main criticism against the widespread adaptation of brachytherapy for the treatment of brain metastases is the high incidence of RN that has historically been
associated with this technique [9]. Rogers et al. reported
23% rate of radiation necrosis when using high-dose
temporary brachytherapy, such as the IsoRay Gliasite
balloon [15]. Using continuous low-dose permanent 125I
brachytherapy, Bogart et al. reported 0% rates of radiation necrosis, yet only achieved 80% rate of local control
[16]. Alternatively, Huang et al. reported 26% rate of radiation necrosis, also using permanent 125I brachytherapy,
while achieving 95% local control rate [12]. The disparity
in results between these two series can be understood if
attention is given to the activity and dose prescribed in
each case. Bogart et al. employed seeds with activity of
0.32-0.45 mCi and a cumulative dose of 80-160 Gy [15],
while Huang et al. implanted seeds with a median activity of 0.79 mCi and delivered a median dose of 400 Gy to
a depth of 5 mm [12]. Based on these data, Huang et al.
concluded that decreasing both the seed activity as well
as the prescription dose will likely result in a decrease
of RN, while minimally impacting local control rates.
The prospective trial for 131Cs was carefully designed to
take into account the aforementioned factors in an attempt
to limit the incidence of RN while maintaining local control.
The lowered seed activity of 131Cs and our utilized dose
prescription not only achieved a high-rate of local control
(100%), but also resulted in zero incidences of RN [8].
In addition to the study design that was used when
employing 131Cs, the physical characteristic of creating
more lower dose gradient isodose lines to the source has
likely contributed to its success. In this analysis, we have
shown that even when using the same prescription dose
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parameters as 131Cs, 125I allows for significantly higher
amount of brain tissue being exposed to radiation. Apart
from irradiating lower volumes of brain tissue, 131Cs also
delivers significantly lower doses to equivalent volumes
of CTV when compared to 125I. Additionally, the higher HI of 131Cs indicated more uniform dosing within the
CTV. Lastly, the CI of 131Cs was closer to 1, indicating that
the prescription dose was delivered more accurately to
the desired volume of CTV. With 125I, not only was there
less uniformity of dosing within the CTV, but the total
volume receiving the prescription dose was also nearly
double the desired volume of CTV. We believe that these
factors may be particularly pertinent when looking at RN
as an endpoint. Dagnew et al. stated that in their study,
both patients who presented with symptomatic RN had
lesions that exceeded 3 cm in diameter [11]. Due to the size
of their lesions, a greater number of seeds were required
to cover the cavity, resulting in a total radiation activity
greater than 40 mCi. These results suggest a dose-dependent risk of RN. More recently, Petr et al. reported 6% incidence of RN while using permanent 125I brachytherapy
seeds in the setting of post-resected brain metastases [17].
It was noted that the patients in the study had relatively large metastases, and specifically all the patients that
developed RN had lesions larger than 3 cm. Therefore,
when compared to 125I, 131Cs limits the surrounding brain
tissue from additional radiation, restricts dose delivery
within the CTV, provides more uniform dosing within
CTV, and accurately targets the desired area. These factors, in turn, may contribute to minimizing the incidences
of RN. These characteristic of 131Cs probable allow it to be
utilized even when dealing with cavities > 3 cm.
Some studies have demonstrated an improved control with dose escalation [18,19,20], particularly in tumors
receiving an equivalent dose in 2 Gy fractions (EQD2)
> 35 Gy (α/β = 10) or biological effective dose using an
α/β = 12 (BED 12) > 40 Gy (linear quadratic cubic model).
There are newer prospective reports of using GammaTile
(a 131Cs radioisotope embedded into collagen), which utilizes very high doses of radiation, similar to our studies.
The doses of 80 Gy prescribed to 5 mm depth are extracted from the use of 131Cs in the prostate. Dose escalation in
brain metastases and primary brain tumors appear promising in the radiation literature. We have utilized a conversion from dose from low-dose-rate to high-dose-rate,
using a dose factor of 0.54 [21].
It must be noted that dosimetric superiority may not
always translate into better clinical outcomes. Prospective studies, comparing the long-term clinical outcomes
of 131Cs and 125I, need to be performed to elucidate this
point. Despite this, our RN levels of 0% with 131Cs are
very encouraging and may provide a glimpse into its potential long-term clinical benefits compared to 125I. It must
also be noted that RN is a multifactorial complication and
likely depends not only on the inherent dosimetric characteristics of the radioisotope, but also on study-specific
factors, such as the prescribed dose levels, seed activity
levels, etc. It should also be mentioned, that because the
strength and position of the 125I sources were not optimized, it could contribute to the quality of its dosimetry.
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Another feature that impacts the incidence of RN is
the length of time, over which the seed can deliver its intended dose as well as the dynamics of the cavity during
that time. It was recently reported that the cavity size is
not significantly reduced in size during the 33-day period, during which 131Cs delivers 90% of its intended dose
[22,23]. However, when dealing with an isotope, such
as 125I, which takes 120 days to deliver the equivalent
dose, a cavity may undergo significant shrinkage. When
the cavity does undergo shrinkage, this means that the
prescription dose is being delivered to a larger volume
of surrounding tissue over time rather than the intended
CTV volume. We believe that this fact may also contribute to the increased incidence of RN, when employing 125I
compared to 131Cs.

Conclusions
In this study, we report that 131Cs permanent bra
chytherapy for the treatment of brain metastases exposes
lower volumes of brain tissue to radiation, provides more
uniform dosing within CTV, and targets the desired CTV
volume more accurately, when compared to 125I. These
findings coupled with advantageous physical characteristics of 131Cs, namely a shorter T1/2, shorter time of dose
delivery, minimal volume of cavity shrinkage, and more
compact dose distribution, provide a dosimetric superio
rity to 125I. The results of this analysis may provide a rationale for the 0% incidence of RN, when treated with
maximally safe neurosurgical resection and intra-operative 131Cs implantation in patients with newly resected
brain metastases.
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